{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:21:59Z","timestamp":1778001719049,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.iac.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:20:40Z","timestamp":1599931240000},"page":"687-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases"],"prefix":"10.1016","volume":"40","author":[{"given":"Linda","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.iac.2020.06.008_bib1","article-title":"House dust mite avoidance measures for perennial allergic rhinitis","author":"Sheikh","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib2","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.anai.2012.02.015","article-title":"Environmental assessment and exposure control: a practice parameter\u2013furry animals","volume":"108","author":"Portnoy","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0091-6749(89)90006-7","article-title":"The effect of cat removal on allergen content in household-dust samples","volume":"83","author":"Wood","year":"1989","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaci.2004.04.036","article-title":"Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: results from the National Survey of Lead and Allergens in Housing","volume":"114","author":"Arbes","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaip.2014.01.003","article-title":"The Special Challenge of Nonadherence With Sublingual Immunotherapy","volume":"2","author":"Bender","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol In Pract"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/all.12890","article-title":"Allergen-specific immunotherapy: is it vaccination against toxins after all?","volume":"72","author":"Bachmann","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2020.06.008_bib7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(00)78276-6","article-title":"Prophylactic inoculation against hay fever","volume":"1","author":"Noon","year":"1911","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iac.2020.06.008_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaci.2013.12.1088","article-title":"Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens","volume":"133","author":"Akdis","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.008_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.008_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaci.2010.08.030","article-title":"Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study","volume":"126","author":"Marogna","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2014.01.010","article-title":"Allergy immunotherapy adherence and delivery route: location does not matter","volume":"2","author":"Cox","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol In Pract"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/all.12600","article-title":"Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials","volume":"70","author":"Senti","year":"2015","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.iac.2019.09.008","article-title":"Sublingual and Patch Immunotherapy for Food Allergy","volume":"40","author":"Waldron","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2020.06.008_bib15","article-title":"FDA cancels AdCom meeting for DBV\u2019s peanut allergy patch, citing efficacy concerns","author":"Dearment","year":"2020","journal-title":"MedCityNews"},{"issue":"46","key":"10.1016\/j.iac.2020.06.008_bib16","doi-asserted-by":"crossref","first-page":"17908","DOI":"10.1073\/pnas.0803725105","article-title":"Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial","volume":"105","author":"Senti","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12931-016-0324-9","article-title":"Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial","volume":"17","author":"Hylander","year":"2016","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.iac.2020.06.008_bib18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaci.2013.07.033","article-title":"Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?","volume":"132","author":"Witten","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.008_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/all.13749","article-title":"EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma","volume":"74","author":"Agache","year":"2019","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaci.2012.12.672","article-title":"Atopic dermatitis: a practice parameter update 2012","volume":"131","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.008_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.anai.2016.12.009","article-title":"Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update","volume":"118","author":"Greenhawt","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2500\/aap.2020.41.200001","article-title":"Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI\/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy","volume":"41","author":"Bernstein","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.iac.2020.06.008_bib24","series-title":"Immunotherapies for allergic disease. 1","first-page":"355","article-title":"Anti-IgE therapy","author":"Polk","year":"2019"},{"issue":"3","key":"10.1016\/j.iac.2020.06.008_bib25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and Fc\u00ce\u03bcRI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","article-title":"Omalizumab treatment downregulates dendritic cell FcepsilonRI expression","volume":"112","author":"Prussin","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2020.06.008_bib29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.iac.2020.06.008_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib33","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14712598.2013.795943","article-title":"Omalizumab for treatment of allergic rhinitis","volume":"13","author":"Vashisht","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib34","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1 supplement","key":"10.1016\/j.iac.2020.06.008_bib36","first-page":"17","article-title":"Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in patients with persistent symptomatic asthma inadequately controlled with inhaled corticosteroids","volume":"102","author":"Massanari","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib37","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib39","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mai.2002.121949","article-title":"Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis","volume":"109","author":"Kuehr","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2005.08.060","article-title":"The \"black box\" warning and allergy drugs","volume":"117","author":"Aaronson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib41","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.008_bib42","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.008_bib45","series-title":"Data on file","year":"2008"},{"issue":"11","key":"10.1016\/j.iac.2020.06.008_bib47","doi-asserted-by":"crossref","first-page":"e0166833","DOI":"10.1371\/journal.pone.0166833","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2020.06.008_bib48","series-title":"Immunotherapies for allergic disease","article-title":"Effect of immunomodulators on allergen immunotherapy","author":"Rosenwasser","year":"2019"},{"issue":"8 Suppl","key":"10.1016\/j.iac.2020.06.008_bib49","first-page":"S115","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena-Woods","year":"2017","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib51","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J\u00a0Dermatol Sci"},{"issue":"26","key":"10.1016\/j.iac.2020.06.008_bib52","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2020.06.008_bib53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.iac.2019.12.006","article-title":"The role of biologics in the treatment of nasal polyps","volume":"40","author":"Franzese","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"issue":"10209","key":"10.1016\/j.iac.2020.06.008_bib54","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic Rhinosinusitis with Nasal Polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol In Pract"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A\u00a0clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib57","first-page":"69","article-title":"The cost-effectiveness of allergen immunotherapy compared with pharmacotherapy for treatment of allergic rhinitis and asthma","volume":"40","author":"Cox","year":"2020","journal-title":"Immunol Allergy Clin"},{"issue":"4","key":"10.1016\/j.iac.2020.06.008_bib58","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jaci.2012.12.662","article-title":"Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis","volume":"131","author":"Hankin","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"27","key":"10.1016\/j.iac.2020.06.008_bib59","doi-asserted-by":"crossref","first-page":"vi","DOI":"10.3310\/hta17270","article-title":"A\u00a0systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis","volume":"17","author":"Meadows","year":"2013","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.iac.2020.06.008_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2500\/aap.2014.35.3708","article-title":"Sublingual immunotherapy for aeroallergens: status in the United States","volume":"35","author":"Cox","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.iac.2020.06.008_bib61","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.fct.2004.08.008","article-title":"A randomized, double-blinded, placebo-controlled oral challenge study to evaluate the allergenicity of commercial, food-grade fish gelatin","volume":"42","author":"Hansen","year":"2004","journal-title":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:53Z","timestamp":1760179433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856120300436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0889856120300436"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.008","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}